1 Wang J,Xia TY,Wang YJ,et al.Long-term results of gammaray-based stereotactic body radiation therapy in treatment of medically unfit or inoperable non-metastatic pancreatic adenocarcinoma[J].Int J Radiat Oncol Biol Phys,2012,84(S3):815-816. 2 Xia T,Li HQ,Wang J,et al.Clinical outcome of hypofractionated radiation therapy for lung,liver,and pancreatic cancer[J].Int J Radiat Oncol Biol Phys,2010,78(S3):574-575. 3 Ikeda M,Ioka T,Ito Y,et al.A multicenter phase II trial of S1 with concurrent radiation therapy for locally advanced pancreatic cancer[J].Int J Radiat Oncol Biol Phys,2013,85(1):163-169. 4 Ren G,Xia T,Wang Y,et al.IMRT with capecitabine in advanced pancreatic cancer.In regard to Passoni.[J].Int J Radiat Oncol Biol Phys,2014,89(2):431-431. 5 McGinn CJ,Zalupski MM,Shureiqi I,et al.Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer[J].J Clin Oncol,2001,19(22):4202-4208. 6 Small W Jr,Berlin J,Freedman GM,et al.Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer:A multicenter phase II trial[J].J Clin Oncol,2008,26(6):942-947. 7 Xia T,Chang D,Wang Y,et al.Dose escalation to target volumes of helical tomotherapy for pancreatic cancer in the phase I-II clinical trial[A].Int J Radiat Oncol Biol Phys,2013,87(2):S303-S303. 8 Huang J,Robertson JM,Ye H,et al.Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma[J].Int J Radiat Oncol Biol Phys,2012,83(4):1120-1125. 9 Nakamura A,Shibuya K,Matsuo Y,et al.Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2012,84(2):369-375. 10 Murphy JD,Christman-Skieller C,Kim J,et al.A dosimetric model of duodenal toxicity after stereotactic body radiotherapy[J].Int J Radiat Oncol Biol Phys,2010,78(5):1420-1426. 11 Cattaneo GM,Passoni P,Longobardi B,et al.Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma[J].Radiother Oncol,2013,108(1):66-71. 12 Kelly P,Das P,Pinnix CC,et al.Duodenal toxicity after fractioned chemoradiation for unresectable pancreatic cancer[J].Int J Radiat Oncol Biol Phys,2013,85(3):143-149. 13 Yoon H,Oh D,Park HC,et al.Predictive factors for gastroduodenal toxicity based on endoscopy following radiotherapy in patients with hepatocellular carcinoma[J].Strahlenther Onkol,2013,189(7):541-546. 14 Simpson DR,Song WY,Moiseenko V,et al.Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patientsundergoing intensity modulated radiation therapy and concurrent cisplatin.[J].Int J Radiat Oncol Biol Phys,2012,83(1):81-86. 15 Murphy JD,Adusumilli S,Griffith KA,et al.Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer[J].Int J Radiat Oncol Biol Phys,2007,68(3):801-808. 16 De Lange SM,van Groeningen CJ,Meijer OW,et al.Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer[J].Eur J Cancer,2002,38(9):1212-1217. |